Zydus Cadila Takes Teva To Virginia Court Asserting Rights Over Risperidone APIs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As the battle for six-month exclusivity on blockbuster drugs going off-patent intensifies in the U.S., generic companies are opening up a new war front - the quest for patent rights over bulk drugs or active ingredients that go into manufacturing multi-billion dollar drugs